Drug intelligence / Profile preview

PDE5 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral, Parenteral
01

Overview

PDE5 siRNA refers to small interfering RNA molecules designed to selectively silence the expression of phosphodiesterase 5 (PDE5). In preclinical research, PDE5 siRNA has been utilized to investigate the role of PDE5 in various pathological conditions, including erectile dysfunction, colorectal cancer, breast cancer, and renal cell carcinoma. By knocking down PDE5 expression, these siRNA molecules prevent the hydrolysis of cyclic guanosine monophosphate (cGMP), leading to cGMP accumulation and subsequent activation of protein kinase G (PKG) signaling. In oncology models, PDE5 knockdown via siRNA has been shown to induce apoptosis, inhibit cell proliferation, and suppress Wnt/beta-catenin-mediated transcription in tumor cells.

Other names
PDE5 small interfering RNAPDE-5 small interfering RNAPDE 5 small interfering RNAphosphodiesterase 5 siRNAphosphodiesterase5 siRNAphosphodiesterase-5 siRNAphosphodiesterase type 5 siRNA
02

Targets

CCND1 (Cyclin D1)PDE5 (Phosphodiesterase 5A)CTNNB1 (Beta-catenin)

Beyond the preview

Go deeper on PDE5 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDE5 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call